stockrowTwist Bioscience Corporation
TWST Healthcare Biotechnology
Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.
- Revenue
- +23.2%
- EPS
- −264.7%
- Free cash flow
- −7.23%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
Follow TWST
Alert me
Twist Bioscience Corporation (TWST) Piotroski F-score
Twist Bioscience Corporation's Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 0.00 |
| FY2024 | 4 | 0.00 |
| FY2023 | 4 | 0.00 |
| FY2022 | 4 | 1.00 |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | (1.00) |
| FY2019 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (12.37%) | (30.02%) | Fail | 0 |
| Positive operating cash flow | (47.63m) | (64.09m) | Fail | 0 |
| Rising return on assets | (12.37%) | (30.02%) | Pass | 1 |
| Cash flow above net income | 30.04m | 144.63m | Pass | 1 |
| Falling long-term leverage | 0.02 | 0.00 | Fail | 0 |
| Rising current ratio | 3.64 | 4.88 | Fail | 0 |
| No new shares issued | 59,808,000 | 58,016,000 | Fail | 0 |
| Rising gross margin | 50.72% | 42.61% | Pass | 1 |
| Rising asset turnover | 0.60 | 0.45 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TECH Bio-Techne Corp compare | 9 |
| BMRN BioMarin Pharmaceutical Inc. compare | 5 |
| JAZZ Jazz Pharmaceuticals PLC compare | 5 |
| KYMR Kymera Therapeutics, Inc. compare | 4 |
| TWST Twist Bioscience Corporation | 4 |
| SMMT Summit Therapeutics PLC compare | 3 |
| CAI Caris Life Sciences,�Inc. compare | — |
| MDGL Madrigal Pharmaceuticals, Inc. compare | — |
| PCVX Vaxcyte, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover